5.60
-0.17(-2.95%)
Currency In USD
| Previous Close | 5.77 |
| Open | 5.6 |
| Day High | 5.82 |
| Day Low | 5.53 |
| 52-Week High | 20.75 |
| 52-Week Low | 5.43 |
| Volume | 1.09M |
| Average Volume | 1.37M |
| Market Cap | 256.02M |
| PE | -3.2 |
| EPS | -1.75 |
| Moving Average 50 Days | 6.52 |
| Moving Average 200 Days | 9.53 |
| Change | -0.17 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $145.08 as of November 17, 2025 at a share price of $5.6. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $1,311.48 as of November 17, 2025 at a share price of $5.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caprock Announces Commencement of Drill Program at Destiny
Newsfile
Nov 11, 2025 1:00 PM GMT
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Caprock Mining Corp. (CSE:CAPR) ("Caprock" or the "Company") is pleased to announce that following the receipt of 'Permis d'intervention' (the "Intervention Permit") from the Quebec government'
Caprock Announces Option and RSU Grant
Newsfile
Nov 05, 2025 12:56 PM GMT
Toronto, Ontario--(Newsfile Corp. - November 5, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") announces that its Board of Directors approved on November 4, 2025, the granting of 750,000 options (the "Options") to a director of
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
GlobeNewswire Inc.
Nov 03, 2025 2:15 PM GMT
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, I